Who Is Eligible for GLP-1 Weight Loss Medications?
FDA Eligibility Criteria
Typically, FDA guidelines for prescribing single or dual GIP/GLP-1 receptor agonists for chronic weight management require a body mass index (BMI) of 30 or higher (obesity), or a BMI of 27 (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Retatrutide Clinical Trial Criteria
The TRIUMPH Phase 3 study program followed similar baseline criteria. It selected participants with obesity thresholds and measured primary endpoints concerning percentage change in body weight from baseline to extended timeframes up to 48 weeks.
GLP-1 Medications Currently Available
Current FDA-approved once-weekly options specifically labeled for weight loss include Semaglutide (Wegovy) and Tirzepatide (Zepbound). Ozempic and Mounjaro carry the same active ingredients respectively but are indicated for Type 2 Diabetes.
When Will Retatrutide Be Available?
Lilly is expected to file its New Drug Application in late 2026, leading to an approximated Prescription Drug User Fee Act (PDUFA) date targeting October 2027 for a finalized approval decision.
Frequently Asked Questions
What BMI do I need for GLP-1 medication?
Most GLP-1 medications for weight loss require a BMI of 30 or greater, or 27 or greater with at least one weight-related health condition.
Can I get retatrutide now?
Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program) and is not yet FDA-approved.
What if my BMI is below 27?
Standard eligibility criteria require a minimum BMI, but some providers may consider off-label use.
How is BMI calculated?
BMI = weight (kg) / height (m)². For imperial units: BMI = (weight (lbs) × 703) / height (inches)².
Disclaimer:
This tool is for educational and informational purposes only. It does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA or EMA. Always consult your healthcare provider before starting or modifying any medication.